The role of A20 in the pathogenesis of lymphocytic malignancy

Cancer Cell International

Yangqiu Li³  Lijiang Yang²  Fan Zhang¹ 

[1] College of Life science and Bio-pharmaceutical, Guangdong Pharmaceutical University, Guangzhou 510006, China;Institute of Hematology, Medical College, Jinan University, Guangzhou 510632, China;Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou 510632, China

关键词: Lymphocytic malignancy;    Tumor suppressor;    NF-κB;    A20 (TNFAIP3);   

Others  :  794689
DOI  :  10.1186/1475-2867-12-44

 received in 2012-10-21, accepted in 2012-11-04,  发布年份 2012

【 摘 要 】

Autoimmune phenomena were identified in many different cases of hematological diseases and solid tumors, which may be due to alterations in the expression and function of the NF-κB signaling pathway. Recently, a number of studies have shown that the deletion or mutation of A20, a negative regulator of NF-κB, is frequently found in lymphomas, suggesting that it may be a linker between the altered immune response and leukemogenesis. The aim of this review is to summarize current findings of the A20 biological functions and its molecular mechanism as a tumor suppressor and immune regulator. The identification of A20 mutations and deletions in lymphocytic malignancy and the predictive significance of these aberrations are also reviewed.

【 授权许可】

   
2012 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chanudet E, Huang Y, Zeng N, Streubel B, Chott A, Raderer M, Du M-Q: TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. B J Haematol 2011, 154(4):533-535.
• [2]Opipari AW Jr, Boguski MS, Dixit VM: The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J B Chem 1990, 265(25):14705-14708.
• [3]Dixit VM, Green S, Sarma V, Holzman LB, Wolf FW, O'Rourke K, Ward PA, Prochownik EV, Marks RM: Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J B chem 1990, 265(5):2973-2978.
• [4]Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA: Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995, 154(4):1699-1706.
• [5]Vereecke L, Beyaert R, van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30(8):383-391.
• [6]Hymowitz SG, Wertz IE: A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 2010, 10(5):332-341.
• [7]Evans PC, Ovaa H, Hamon M, Kilshaw PJ, Hamm S, Bauer S, Ploegh HL, Smith TS: Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J 2004, 378:727-734.
• [8]Wertz IE, O'Rourke KM, Zhou HL, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, et al.: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappa B signalling. Nature 2004, 430(7000):694-699.
• [9]Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam C, Phu L, Phung Q, Maurer B, Arnott D, et al.: Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol Cell 2010, 40(4):548-557.
• [10]Beyaert R, Heyninck K, Van Huffel S: A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 2000, 60(8):1143-1151.
• [11]Opipari AW Jr, Hu HM, Yabkowitz R, Dixit VM: The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992, 267(18):12424-12427.
• [12]Jaattela M, Mouritzen H, Elling F, Bastholm L: A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol 1996, 156(3):1166-1173.
• [13]Song HY, Rothe M, Goeddel DV: The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A 1996, 93(13):6721-6725.
• [14]Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 1992, 267(25):17971-17976.
• [15]Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C: A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem 1996, 271(30):18068-18073.
• [16]Sarma V, Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ, Dixit VM: Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995, 270(21):12343-12346.
• [17]Laherty CD, Perkins ND, Dixit VM: Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J Biol Chem 1993, 268(7):5032-5039.
• [18]Miller WE, Mosialos G, Kieff E, Raab-Traub N: Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol 1997, 71(1):586-594.
• [19]Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM: The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992, 267(34):24157-24160.
• [20]Zhang SQ, Kovalenko A, Cantarella G, Wallach D: Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 2000, 12(3):301-311.
• [21]De Valck D, Heyninck K, Van Criekinge W, Vandenabeele P, Fiers W, Beyaert R: A20 inhibits NF-kappaB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun 1997, 238(2):590-594.
• [22]Ferran C, Stroka DM, Badrichani AZ, Cooper JT, Wrighton CJ, Soares M, Grey ST, Bach FH: A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998, 91(7):2249-2258.
• [23]Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, Haegeman G, Beyaert R: The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 1999, 145(7):1471-1482.
• [24]Liu YC, Penninger J, Karin M: Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol 2005, 5(12):941-952.
• [25]Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D: A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009, 182(12):7718-7728.
• [26]Malinverni C, Unterreiner A, Staal J, Demeyer A, Galaup M, Luyten M, Beyaert R, Bornancin F: Cleavage by MALT1 induces cytosolic release of A20. Biochem Biophys Res Commun 2010, 400(4):543-547.
• [27]Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R: Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol 2010, 80(12):2009-2020.
• [28]Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, et al.: Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459(7247):712-716.
• [29]Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008, 9(3):263-271.
• [30]Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, Soberon V, Schenten D, Mack B, Reutelshofer M, et al.: B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011, 117(7):2227-2236.
• [31]Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 2008, 14(3):258-265.
• [32]Wang X, Friesen J, Nishanth G, Thi XN, Matuschewski K, Schluter D: Hepatocyte-specific knockout of A20 augments defense against malaria liver stage infections. Int J Med Microbiol 2011, 301:42-43.
• [33]Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, et al.: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(7247):717-721.
• [34]Shembade N, Harhaj EW: Regulation of NF-kappaB signaling by the A20 deubiquitinase. Cell Mol Immunol 2012, 9(2):123-130.
• [35]Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D: Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009, 10(5):466-473.
• [36]Inomata M, Niida S, Shibata K, Into T: Regulation of Toll-like receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell Mol Life Sci 2012, 69(6):963-979.
• [37]Shembade N, Harhaj E: A20 inhibition of NF-κB and inflammation: Targeting E2:E3 ubiquitin enzyme complexes. Cell Cycle 2010, 9(13):10-11.
• [38]Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE, Harhaj EW: The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008, 9(3):254-262.
• [39]Bousquet M, Harris MH, Zhou BY, Lodish HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A 2010, 107(50):21558-21563.
• [40]Guo SQ, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, Purton LE, Fleming HH, Cobb B, Merkenschlager M, et al.: MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A 2010, 107(32):14229-14234.
• [41]O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D: MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A 2010, 107(32):14235-14240.
• [42]Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY: MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A 2010, 107(50):21505-21510.
• [43]Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM, Baltimore D: MicroRNA-125b potentiates macrophage activation. J Immunol 2011, 187(10):5062-5068.
• [44]Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang DF, Aguiar RCT: MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappa B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 2012, 109(20):7865-7870.
• [45]Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M: TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114(12):2467-2475.
• [46]Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, et al.: The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113(20):4918-4921.
• [47]Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, et al.: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009, 206(5):981-989.
• [48]Nakajima S, Saito Y, Takahashi S, Hiramatsu N, Kato H, Johno H, Yao J, Paton AW, Paton JC, Kitamura M: Anti-inflammatory subtilase cytotoxin up-regulates A20 through the unfolded protein response. Biochem Biophys Res Commun 2010, 397(2):176-180.
• [49]Yan QG, Huang YX, Watkins AJ, Kocialkowski S, Zeng NY, Hamoudi RA, Isaacson PG, de Leval L, Wotherspoon A, Du MQ: BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 2012, 97(4):595-598.
• [50]Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J, Wotherspoon A, Isaacson PG, Ferry J, Du MQ: A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010, 24(2):488-489.
• [51]Braun FC, Grabarczyk P, Mobs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, Schroder J, Delin M, et al.: Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011, 25(9):1494-1501.
• [52]Giulino L, Mathew S, Ballon G, Chadburn A, Barouk S, Antonicelli G, Leoncini L, Liu YF, Gogineni S, Tam W, et al.: A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. Blood 2011, 117(18):4852-4854.
• [53]Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, Wiestler OD, Siebert R, Kuppers R, Deckert M: Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 2010, 120(4):529-535.
• [54]Philipp C, Edelmann J, Buhler A, Winkler D, Stilgenbauer S, Kuppers R: Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. Int J Cancer 2011, 128(7):1747-1750.
• [55]Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C, et al.: Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer 2011, 128(10):2495-2500.
• [56]Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA: Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int 2007, 7:14. BioMed Central Full Text
• [57]Vereecke L, Beyaert R, van Loo G: Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011, 39(4):1086-1091.
• [58]Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 2011, 4:36. BioMed Central Full Text
• [59]Ayala R, Martinez-Lopez J, Gilsanz F: Acute myeloid leukemia and transcription factors: role of erythroid Kruppel-like factor (EKLF). Cancer Cell Int 2012, 12(1):25. BioMed Central Full Text
• [60]Wu ZL, Song YQ, Shi YF, Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011, 4(1):31. BioMed Central Full Text
• [61]Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y: Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol 2011, 4:21. BioMed Central Full Text
• [62]Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y: Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2010, 3(1):44. BioMed Central Full Text